Education
About Us
Working with TipRanks
Follow Us
Opko Health Inc (OPK)
NASDAQ:OPK
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.11Last Year’s EPS
-0.01Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: -3.62%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call for OPKO Health highlighted strategic moves such as the sale of BioReference's oncology business to Labcorp and promising developments in their GLP-1/glucagon agonist and ModeX's clinical trials. However, these positives were offset by declines in revenue in the Diagnostics segment, increased operating loss in the Pharmaceutical segment, and a net loss for the quarter. The sentiment is mixed due to significant achievements and ongoing financial challenges.Company Guidance
During the OPKO Health First Quarter 2025 Financial Results Conference Call, several key metrics and guidance points were highlighted. The company reported a net loss of $67.6 million, or $0.10 per share, compared with a net loss of $81.8 million or $0.12 per share for the same period last year. Revenue from the Diagnostics segment was $102.8 million, reflecting a decrease from $126.9 million in the prior year, partly due to the sale of certain assets to Labcorp. The Pharmaceuticals segment revenue was $47.1 million, with product revenue including Rayaldee at $6.3 million. R&D expenses increased to $30.2 million, driven by ModeX development activities. OPKO expects total annual revenues between $675 million and $685 million, with contributions from various segments and strategic transactions. The company also anticipates a gain of approximately $100 million from the Labcorp transaction and continues to target improved profitability across its business segments.BioReference Oncology Business Sale
OPKO Health announced the sale of BioReference's oncology and related clinical testing business to Labcorp for up to $225 million, including $192.5 million payable at closing and up to $32.5 million in earn-outs.
Positive Progress in GLP-1/Glucagon Agonist Development
OPKO's dual-GLP-1 glucagon agonist, OPKO-88006, showed promising results in animal models for obesity and NASH. A collaboration with Entera Bio aims to develop an oral tablet form using Entera's N-Tab technology.
ModeX Phase 1 Clinical Trials
ModeX, OPKO's subsidiary, continues its Phase 1 clinical trials for its Epstein-Barr virus vaccine in collaboration with Merck, and MDX2001, a tetraspecific antibody for solid tumor cancers.
Cost Reductions and Workforce Optimization
BioReference eliminated 136 positions, representing a 7% workforce reduction, leading to estimated annualized cost savings of $19 million.
Strong Cash Position
OPKO ended Q1 2025 with approximately $450 million in cash, cash equivalents, and restricted cash.
---
OPK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OPK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2025 | $1.38 | $1.35 | -2.17% |
Feb 27, 2025 | $1.63 | $1.74 | +6.75% |
Nov 07, 2024 | $1.45 | $1.52 | +4.83% |
Aug 07, 2024 | $1.28 | $1.43 | +11.72% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Opko Health Inc (OPK) report earnings?
Opko Health Inc (OPK) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Opko Health Inc (OPK) earnings time?
Opko Health Inc (OPK) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OPK EPS forecast?
OPK EPS forecast for the fiscal quarter 2025 (Q2) is -0.11.
---